相关实验视频
Updated: Jan 12, 2026

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
786
估计阿尔茨海默病生物标志物变化的时间进程
Lars Lau Raket1,2, Alexa Pichet Binette1, Niklas Mattsson-Carlgren1,3,4
1Clinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, 223 62 Lund, Sweden.
Brain : a journal of neurology
|November 3, 2025
概括
阿尔茨海默病的进展时间从最初的生物标志物变化开始为20-25年,前症状阶段为7-11年. 这项研究绘制了关键的阿尔茨海默病生物标志物随着时间的推移而发生的变化.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
- 疾病进展建模 疾病进展建模
背景情况:
- 阿尔茨海默病 (AD) 诊断正在从基于症状的转向生物标准.
- 新的AD治疗需要了解几十年的生物进展时间表.
- 纵向数据对于绘制AD生物标志物演变的地图至关重要.
研究的目的:
- 建立基于生物标志物变化的阿尔茨海默病的连续疾病时间表.
- 在AD连续线上绘制各种生物标志物 (Aβ,tau,神经退行) 的轨迹.
- 通过现有方法和认知措施验证一种新的分期方法.
主要方法:
- 利用了来自ADNI和BioFINDER队列 (n=3,536) 的粉样β (Aβ) PET和认知测试 (MMSE,ADAS-cog) 的纵向数据.
- 根据Aβ-PET阳性后的预测时间,估计了持续的疾病时间表.
- 绘制了Aβ,tau和神经退行症的生物标志物轨迹 (血,脑脊液,MRI,PET) 的地图.
主要成果:
- 拟议的分阶段方法与其他方法 (例如PET时钟) 相比,与未见的认知措施和生物标志物有更强的相关性.
- 从Aβ-PET阳性到严重痴呆的预估疾病持续时间为20-25年,预症状阶段为7-11年.
- 详细介绍了生物标记异常的时间序列,其中CSF Aβ42/40在Aβ-PET阳性之前,神经退行症标记在以后出现.
结论:
- 疾病进展建模为了解AD生物标志物和认知演变提供了强大的框架.
- 建立的时间表有助于确定阿尔茨海默病的阶段,改善预后和治疗评估.
- 这些发现突显了从最初的生物标志物变化到严重的AD痴呆症的关键20年的跨度.
更多相关视频
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
4.6K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.2K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801